Halozyme | search
Click here to view Halozyme news from 60+ newspapers.
Bookmark or Share- Drug Delivery Technologies - HalozymeENHANZE ® technology helps break through subcutaneous volume limitations to facilitate rapid high-dose, high-volume subcutaneous drug delivery.. Learn more about ENHANZE ® technology
- Reinventing the patient experience. | HalozymeThe patient is at the forefront of everything we do at Halozyme. With our disruptive drug delivery technologies and robust commercial portfolio, we are committed to reinventing the patient experience by easing the burden of treatment and improving patient outcomes.
- Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo ...Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval for Opdivo Qvantig™ (nivolumab and ...
- Halozyme Announces Positive Clinical Data of its High-Volume Auto ...Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE ® in 30 seconds using Halozyme's proprietary high-volume auto...
- Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ...As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of...
More
